Analysts have advised investors to buy Tata Steel Ltd., Prestige Estates Ltd. and Divis Laboratories Ltd. among other stocks on Wednesday.Kunal Rambhia, founder, The Street, Shrikant Chouhan, executive vice president, head equity research, Kotak Securities, and Aditya Agarwala, head of research and investments, Invest4edu shared their insights with NDTV Profit.Tata SteelChouhan recommended purchasing the stock with a target of Rs 150 and a stop loss of Rs 141. Over the past year, the stock has fallen 12.06%. Its relative strength index was at 54.05.Out of 34 analysts tracking the company, 20 maintain a 'buy', eight recommend a 'hold' rating and six suggest 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 7.9%.PrestigeChouhan also has a 'buy' call on Prestige Estates, with a target of Rs 1,275 and a stop loss of Rs 1,360. Over the past year, the stock has fallen 9.43%. Its relative strength index was at 58.89.Out of 20 analysts tracking the company, 17 maintain a 'buy' rating, two recommend a 'hold' and one suggests 'sell', according to Bloomberg data. The average 12-month analysts' consensus price target implies an upside of 30.7%.Stock Market Today: All You Need To Know Going Into Trade On May 7Divi's LaboratoriesAgarwala recommends purchasing the stock with a target of Rs 6,460 and a stop loss of Rs 5,960. Over the past year, the stock has risen 57.51%. Its relative strength index was at 42.33.Out of 30 analysts tracking the company, 12 maintain a 'buy' rating, 12 suggest 'sell' and six recommend a 'hold', according to Bloomberg data. The average 12-month analysts' consensus price target implies a downside of 3.3%.Balkrishna IndustriesRambhia recommended purchasing the stock with a target of Rs 2,900 and a stop loss of Rs 2,675. Over the past year, the stock has risen 11.78%. Its relative strength index was at 54.82.Out of 22 analysts tracking the company, 11 maintain a 'buy' rating, five recommend a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 3.1%.Max Healthcare InstituteAgarwala recommends purchasing the stock with a target price of Rs 1,250 and a stop loss of Rs 1,110. Over the past year, the stock has risen 43.57%. Its relative strength index was at 48.23.Out of 23 analysts tracking the company, 15 maintain a 'buy' rating, four recommend a 'hold' and four suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 1%.Stock Market Live: GIFT Nifty Indicates Higher Open; Godrej Consumer, KEI Industries, Defence Stocks In Focus Disclaimer: The views and opinions expressed by the investment advisers on NDTV Profit are of their own and not of NDTV Profit. NDTV Profit advises users to consult with their own financial or investment adviser before taking any investment decision.